Cystine and theanine for chemoradiotherapy-induced esophagitis in non-small cell lung cancer: a prospective observational study.
Chemoradiotherapy
Cystine and theanine
Esophagitis
Lung cancer
Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957
Informations de publication
Date de publication:
03 Jun 2024
03 Jun 2024
Historique:
received:
18
02
2024
accepted:
28
05
2024
medline:
3
6
2024
pubmed:
3
6
2024
entrez:
3
6
2024
Statut:
epublish
Résumé
Although several potential radioprotectants have been explored, radiation esophagitis is still difficult to control. Further development of supportive therapies is required. Our purpose was to investigate the efficacy and safety of cystine and theanine for esophagitis in non-small cell lung cancer (NSCLC) patients undergoing chemoradiotherapy (CRT). This study is a prospective observational study. The participants were recruited from unresectable locally advanced NSCLC who had scheduled to receive weekly paclitaxel or nab-paclitaxel/carboplatin plus radiation therapy (60 Gy in 30 fractions) for 6 weeks. They took an oral amino acid supplement containing 700 mg cystine and 280 mg theanine once daily regardless of CRT timing from the start of CRT until completion. The primary endpoint was the incidence of any grade esophagitis. The secondary endpoints were quality of life (QoL) and adverse events (AEs). A total of 26 patients were evaluated. All participants completed 60 Gy of RT in 30 fractions. The overall incidence of esophagitis was 73%; however, no ≥ grade 3 was reported. There were no AEs likely to be related to cystine and theanine. The mean EuroQoL 5-Dimension 5-Level health index score before and after chemoradiotherapy was 0.952 ± 0.0591 and 0.952 ± 0.0515 (P = 0.89), and the mean Visual Analogue Scale scores before and after treatment were 67.9 ± 15.4 and 79.4 ± 13.2 (P = 0.0047), respectively. Our study showed no severe esophagitis, any AEs, nor QoL decrease in NSCLC patients receiving CRT. Cystine and theanine are potentially effective to reduce severe CRT-induced esophagitis. UMIN000052622, 26 October 2023, retrospectively registered.
Identifiants
pubmed: 38829486
doi: 10.1007/s00520-024-08613-0
pii: 10.1007/s00520-024-08613-0
doi:
Substances chimiques
Cystine
48TCX9A1VT
Glutamates
0
theanine
8021PR16QO
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
400Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Baker S, Fairchild A (2016) Radiation-induced esophagitis in lung cancer. Lung Cancer (Auckl) 7:119–127. https://doi.org/10.2147/LCTT.S96443
doi: 10.2147/LCTT.S96443
pubmed: 28210168
Nesheiwat Z, Akbar H, Kahloon A, Mahajan K (2023) Radiation esophagitis. StatPearls publishing LLC. http://www.ncbi.nlm.nih.gov/books/NBK499920/
Nakajima M, Watanabe B, Han L, Shimizu B, Wada K, Fukuyama K, Suzuki H, Hiratake J (2014) Glutathione-analogous peptidyl phosphorus esters as mechanism-based inhibitors of γ-glutamyl transpeptidase for probing cysteinyl-glycine binding site. Bioorg Med Chem 22(3):1176–1194. https://doi.org/10.1016/j.bmc.2013.12.034
doi: 10.1016/j.bmc.2013.12.034
pubmed: 24411479
Rimaniol AC, Mialocq P, Clayette P, Dormont D, Gras G (2001) Role of glutamate transporters in the regulation of glutathione levels in human macrophages. Am J Physiol Cell Physiol 281(6):C1964–C1970. https://doi.org/10.1152/ajpcell.2001.281.6.C1964
doi: 10.1152/ajpcell.2001.281.6.C1964
pubmed: 11698255
Tsuchiya T, Honda H, Oikawa M, Kakita T, Oyama A, Oishi H, Tochikubo K, Hashimoto T, Kurihara S, Shibakusa T, Kayahara T (2016) Oral administration of the amino acids cystine and theanine attenuates the adverse events of S-1 adjuvant chemotherapy in gastrointestinal cancer patients. Int J Clin Oncol 21(6):1085–1090. https://doi.org/10.1007/s10147-016-0996-7
doi: 10.1007/s10147-016-0996-7
pubmed: 27306219
pmcid: 5124434
Hamaguchi R, Tsuchiya T, Miyata G, Sato T, Takahashi K, Miura K, Oshio H, Ohori H, Ariyoshi K, Oyamada S, Iwase S (2020) Efficacy of oral administration of cystine and theanine in colorectal cancer patients undergoing capecitabine-based adjuvant chemotherapy after surgery: a multi-institutional, randomized, double-blinded, placebo-controlled, phase II trial (JORTC-CAM03). Support Care Cancer 28(8):3649–3657. https://doi.org/10.1007/s00520-019-05205-1
doi: 10.1007/s00520-019-05205-1
pubmed: 31811480
Yoneda J, Nishikawa S, Kurihara S (2021) Oral administration of cystine and theanine attenuates 5-fluorouracil-induced intestinal mucositis and diarrhea by suppressing both glutathione level decrease and ROS production in the small intestine of mucositis mouse model. BMC Cancer 21(1):1343. https://doi.org/10.1186/s12885-021-09057-z
doi: 10.1186/s12885-021-09057-z
pubmed: 34922485
pmcid: 8684148
Palma DA, Senan S, Oberije C, Belderbos J, de Dios NR, Bradley JD, Barriger RB, Moreno-Jiménez M, Kim TH, Ramella S, Everitt S, Rengan R, Marks LB, De Ruyck K, Warner A, Rodrigues G (2013) Predicting esophagitis after chemoradiation therapy for non-small cell lung cancer: an individual patient data meta-analysis. Int J Radiat Oncol Biol Phys 87(4):690–696. https://doi.org/10.1016/j.ijrobp.2013.07.029
doi: 10.1016/j.ijrobp.2013.07.029
pubmed: 24035329
Yamamoto N, Nakagawa K, Nishimura Y, Tsujino K, Satouchi M, Kudo S, Hida T, Kawahara M, Takeda K, Katakami N, Sawa T, Yokota S, Seto T, Imamura F, Saka H, Iwamoto Y, Semba H, Chiba Y, Uejima H, Fukuoka M (2010) Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. J Clin Oncol 28(23):3739–3745. https://doi.org/10.1200/jco.2009.24.5050
doi: 10.1200/jco.2009.24.5050
pubmed: 20625120
Chun SG, Hu C, Choy H, Komaki RU, Timmerman RD, Schild SE, Bogart JA, Dobelbower MC, Bosch W, Galvin JM, Kavadi VS, Narayan S, Iyengar P, Robinson CG, Wynn RB, Raben A, Augspurger ME, MacRae RM, Paulus R, Bradley JD (2017) Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: a secondary analysis of the NRG oncology RTOG 0617 randomized clinical trial. J Clin Oncol 35(1):56–62. https://doi.org/10.1200/jco.2016.69.1378
doi: 10.1200/jco.2016.69.1378
pubmed: 28034064
Ninomiya K, Yokoyama T, Hotta K, Oze I, Katsui K, Hata T, Yoshioka H, Bessho A, Hosokawa S, Kuyama S, Kudo K, Kozuki T, Harada D, Yasugi M, Murakami T, Nakanishi M, Takigawa N, Maeda Y, Kiura K (2021) A randomized trial of sodium alginate prevention of esophagitis in LA-NSCLC receiving chemoradiotherapy: OLCSG1401. Support Care Cancer 29:5237–5244. https://doi.org/10.1007/s00520-021-06092-1
doi: 10.1007/s00520-021-06092-1
pubmed: 33649919
Movsas B, Scott C, Langer C, Werner-Wasik M, Nicolaou N, Komaki R, Machtay M, Smith C, Axelrod R, Sarna L, Wasserman T, Byhardt R (2005) Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98–01. J Clin Oncol 23(10):2145–2154. https://doi.org/10.1200/jco.2005.07.167
doi: 10.1200/jco.2005.07.167
pubmed: 15800308
Sarna L, Swann S, Langer C, Werner-Wasik M, Nicolaou N, Komaki R, Machtay M, Byhardt R, Wasserman T, Movsas B (2008) Clinically meaningful differences in patient-reported outcomes with amifostine in combination with chemoradiation for locally advanced non-small-cell lung cancer: an analysis of RTOG 9801. Int J Radiat Oncol Biol Phys 72(5):1378–1384. https://doi.org/10.1016/j.ijrobp.2008.03.003
doi: 10.1016/j.ijrobp.2008.03.003
pubmed: 18501528
Matsuu-Matsuyama M, Shichijo K, Tsuchiya T, Kondo H, Miura S, Matsuda K, Sekine I, Nakashima M (2020) Protective effects of a cystine and theanine mixture against acute radiation injury in rats. Environ Toxicol Pharmacol 78:103395. https://doi.org/10.1016/j.etap.2020.103395
doi: 10.1016/j.etap.2020.103395
pubmed: 32325407
Kurihara S, Shibakusa T, Tanaka KA (2013) Cystine and theanine: amino acids as oral immunomodulative nutrients. Springerplus 2:635. https://doi.org/10.1186/2193-1801-2-635
doi: 10.1186/2193-1801-2-635
pubmed: 24312747
pmcid: 3851524
Miyagawa K, Hayashi Y, Kurihara S, Maeda A (2008) Co-administration of l-cystine and l-theanine enhances efficacy of influenza vaccination in elderly persons: nutritional status-dependent immunogenicity. Geriatr Gerontol Int 8(4):243–250. https://doi.org/10.1111/j.1447-0594.2008.00483.x
doi: 10.1111/j.1447-0594.2008.00483.x
pubmed: 19149835
Kurihara S, Yoshida S, Sukegawa E, Yoshimura S, Uchida H, Maeda K, Yamamoto T (2008) Evaluation of safety of long-term and excessive intake of l-cystine and l-theanine in healthy adult subjects. Seikatsu Eisei 52:229–236